ASEAN Insight Provider, CrossASEAN Research

Angus Mackintosh

In Equity Sales and Research for more than 25 years covering Asian markets. Possesses in-depth knowledge of a wide range of companies, economies, and markets in Asia. Over his career, he has specialised in HK/China and ASEAN markets at various different Investment Banks, most recently heading equities in Indonesia for Bank of America Merrill Lynch in Jakarta for more than three years. Whilst in Jakarta, he produced a well-read daily and weekly product on the Indonesian market, which included company visits, as well as political, economic and sector commentary. A former racing skier, who enjoys ultra-marathons and surfing in his spare time.

ASEAN Insight Provider

Sido Muncul (SIDO IJ) - Opportunity in Adversity

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

CrossASEAN Research

At CrossASEAN Research we strive to produce unbiased and differentiated on the ground insights on companies across South East Asia. Our Research is produced for the most part after face to face meetings and conversations with company management to dig deep into the long term vision and strategy of the companies we cover. We seek to deliver investable and actionable themes on sectors and markets across SE Asia, often in collaboration with other Insight Providers across the region, pooling the vast experience of the analysts within the Smartkarma Ecosystem. We also offer bespoke work and tailor made trips for our clients. 

Insights across South East Asia

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/industri-jamu-dan-farmasi-sido-muncul-tbk-pt" target="_blank" data-smartkarma-citation="entities:6033:1" rel="noopener">Sido Muncul (SIDO IJ)</a> booked a solid set of 9M2024 results with some seasonal slowdown in 3Q2024 but prospects remain healthy as the rainy season has begun to boost consumption. </li>
<li>The company is seeing strong revenue growth across herbal &amp; supplements, F&amp;B (mainly energy drinks) and pharma, with improving margins, and exceptionally strong export growth. </li>
<li>
<a href="https://www.smartkarma.com/entities/industri-jamu-dan-farmasi-sido-muncul-tbk-pt" target="_blank" data-smartkarma-citation="entities:6033:1" rel="noopener">Sido Muncul</a> saw an increase in its cash conversion caused by a strategic stocking of raw materials at favourable prices which should boost margins. Valuations are attractive at 15x PER. </li>
</ul>



Sido Muncul (SIDO IJ) booked a solid set of 9M2024 results with some seasonal slowdown in 3Q2024 but prospects remain healthy as the rainy season has begun to boost consumption. 
The company is seeing strong revenue growth across herbal &amp; supplements, F&amp;B (mainly energy drinks) and pharma, with improving margins, and exceptionally strong export growth. 

Sido Muncul saw an increase in its cash conversion caused by a strategic stocking of raw materials at favourable prices which should boost margins. Valuations are attractive at 15x PER. 


Sido Muncul (SIDO IJ) - Stocking Up for Growth